|About||Users||Reviews||Exhibitors||Photos||Speakers 90||Travel Deals|
The Difficult to Express Proteins, organized by the Cambridge Healthtech Institute will take place from 3rd November to the 4th November 2014 at the Lisbon Marriott Hotel in Lisbon, Portugal. The conference will cover areas like Controlling glycosylation, folding, immunogenicity, stability, toxic proteins , Managing disulfide bonds, Inclusion bodies, Low yields, Non-active expression results.
Timings12:00 PM - 07:05 PM (Nov 03) (General)
07:30 AM - 06:45 PM (Nov 04) (General)
Entry FeesPaid Ticket Starts from 125 EUR View Details
Category & TypeConference
Medical & Pharma
Editions03 - 04 Nov 2014
Frequency Not Available
Claim this event
OrganizerFollow Company 500 Total Events / 153 Upcoming Events 80+ Followers
Write a ReviewAdd Your Review
Matthew Baker, Ph.DImmunology | Therapeutic Antibodies & Proteins | Research Commercialization at... Cambridge, Canada
Rakesh DixitVice President, R & D at MedImmune (AstraZeneca Biologics) Gaithersburg, United States
Melody SauerbornSenior expert immunogenicity TT/ Founder & CEO ADA InVivo at... Netherlands
Schedule & Agenda
|Mon, 03 Nov 12:00 PM - 01:45 PM||Conference Registration |
|Mon, 03 Nov 01:45 PM - 01:50 PM||PLENARY SESSION |
PEGS Europe Team Welcome
|Mon, 03 Nov 01:50 PM - 02:00 PM||PLENARY SESSION |
Chairpersonu2019s Opening Remarks William Finlay, Ph.D., Director, Global Biotherapeutic Technologies, Pfizer, Inc.
|Mon, 03 Nov 02:00 PM - 02:45 PM||PLENARY SESSION |
The Impact of the New Regulatory Guidance Landscape on the Validation of the Manufacturing Process and the Characterisation of Starting Materials, Drug Substance and Drug Product Steffen GrossSteffen Gross, Ph.D., Head, Monoclonal and Polyclonal Antibodies, Paul-Ehrlich-Institut The regulatory guidance landscape regarding biological products changes rapidly. Documents overseeing process validation is currently facing major overhauls. New guidelines are published defining the requirements for starting materials and excipients. This might have a deep impact not only on the process development of traditional monoclonal antibody type products but also on new antibody formats such as conjugates as well as on new developed formulations.
|Mon, 03 Nov 02:45 PM - 03:30 PM||PLENARY SESSION |
Current Progress with Armed Antibody Products Dario NeriDario Neri, Ph.D., Professor, Chemistry and Applied Biosciences, ETH Zurich There is an emerging trend in Pharmaceutical Biotechnology to u201carmu201d antibodies, capable of selective localization at the site of disease, with suitable therapeutic payloads (e.g., drugs, cytokines, radionuclides, a second antibody moiety, hence producing a bispecific product). This strategy aims at concentrating therapeutic agents in diseased part of the body, while sparing normal tissues. In this lecture, I will present a comparative evaluation of different classes of armed antibody products, developed in my laboratory in collaboration with Philogen. In particular, I will present preclinical and clinical data of armed antibodies in the field of cancer, of chronic inflammation and of endometriosis.
|Mon, 03 Nov 03:30 PM - 04:00 PM||Refreshment Break |
|Mon, 03 Nov 04:00 PM - 04:05 PM||ENGINEERING BETTER HOSTS |
Chairpersonu2019s Opening Remarks
|Mon, 03 Nov 04:05 PM - 04:35 PM||KEYNOTE PRESENTATION |
Production of Protein Tools in Support of R&D Pharma ProjectsJacques DumasJacques Dumas, Ph.D., Head, Protein Production, Global Biotherapeutics, sanofiThe genomic era of the 90u2019s is culminating in the identification and production of novel protein targets for drug discovery. Increasing numbers of u201chigh valueu201d proteins are used for crystallography and High Throughput Screening (HTS). Proteins are produced by recombinant technology and purified to homogeneity using platform strategies. In the last 10 years, strategies have evolved to adapt to difficult to express proteins, such as kinases. In addition, the revival of biotherapeutic proteins has generated the need for new protein tools.
|Mon, 03 Nov 04:35 PM - 05:05 PM||High-Yield, Zero-Leakage Expression System in Escherichia coli |
Yusuke Kato, Ph.D., Senior Researcher, Genetically Modified Organism Research Centre, National Institute of Agrobiological SciencesWe designed a high-yield, zero-leakage expression system using a transcriptional-translational double-regulation for toxic protein production in E. coli. u201cTranslational switchesu201d were constructed using site-specific unnatural amino acid incorporation at the amber stop codons that were inserted in target genes. Under repression conditions, leakage-expression was completely abolished by a synergistic repression both at the transcriptional and translational levels. In contrast, both transcription and translation were fully activated under induction conditions.
|Mon, 03 Nov 05:05 PM - 05:35 PM||Addressing Challenges for Production of Human Proteins and Multi-Protein Complexes Using the Baculovirus Expression System (BEVS) |
Arnaud Poterzman, Research Director, Integrated Structural Biology, IGBMC/CNRSWe present here recent advances for the production of multi-subunit complexes in the baculovirus expression system using human multi-subunit transcription factors as model systems: Vector development for parallel expression/co-expression screening, use of Lambda red recombination in E. coli for manipulation and improvement of the baculoviral genome and assembly of multi-gene constructs from synthetic biology approaches. We will also discuss use of fluorescent proteins as infection makers and of baculovirus-infected insect cells (BIIC) for storage and standardization.
|Mon, 03 Nov 05:35 PM - 06:05 PM||Sponsored Presentation (Opportunity Available) |
|Mon, 03 Nov 06:05 PM - 07:05 PM||Welcome Reception in the Exhibit Hall with Poster Viewing |
|Mon, 03 Nov 07:05 PM - 07:05 PM||End of Day One |
|Tue, 04 Nov 07:30 AM - 07:45 AM||Registration |
|Tue, 04 Nov 07:45 AM - 08:30 AM||Breakfast Presentation (Sponsorship Opportunity Available) or Morning Coffee |
|Tue, 04 Nov 08:30 AM - 08:40 AM||NOVEL STRATEGIES |
|Tue, 04 Nov 08:40 AM - 09:10 AM||Higher Yield u2013 An Ultimate Goal for Biological Product Development: A Case Study about Use of Process Intensification Technology for a Difficult to Express Glycoprotein |
Mallika Singh, Ph.D., Associate Director, Upstream Development & Manufacturing, Teva Biopharmaceuticals USA, Inc.The case study will show the use of an emerging technology (process intensification technology using Alternating Tangential Flow, ATF) which will perhaps be the direction of cell culture manufacturing process for biologics in near future.
|Tue, 04 Nov 09:10 AM - 09:40 AM||Exploring Codon Optimisation Strategies for Production of Membrane Proteins |
Morten Nu00f8rholm, Ph.D., Academic Entrepreneurial Research Group Leader, DTU Biosustain; Technical University of Denmark, Novo Nordisk Foundation Center for BiosustainabilityUsing a library of GFP-tagged membrane proteins, we have compared different codon optimisation strategies including synonymous mutations in the 5u00b4end, complete re-coding using multiparameter optimisation algorithms and complementing rare codon usage with additional copies of the corresponding low-concentration tRNAs.
|Tue, 04 Nov 09:40 AM - 10:10 AM||Chaperones Enable Native Folding of a Disulfide-rich Scorpion Toxin in the E.coli Periplasm |
Andrias Ou2019Reilley, Ph.D., Researcher, Department of Physiology and Pathophysiology, Friedrich-Alexander Universitu00e4t Erlangen-Nu00fcrnbergAnimal neurotoxin peptides are valuable probes for studying ion channel pharmacology. Misfolding through formation of incorrect disulfide isomers has hindered recombinant toxin expression in E.coli. We report that co-secretion of a suite of protein disulphideisomerases and peptidyl-prolylcis/trans-isomerases into the E.coli periplasm boosts expression and produces correct folding of an insecticidal scorpion toxin, as validated by X-ray crystallography.
|Tue, 04 Nov 10:10 AM - 10:50 AM||Coffee Break in the Exhibit Hall with Poster Viewing |
|Tue, 04 Nov 10:50 AM - 11:20 AM||cerevisiae-Based High Yield Expression System for Efficient Purification of High Quality Human/Eukaryotic Membrane Proteins for Structural Studies |
Per Armstrup Pedersen, Ph.D., Professor, Department of Biology, University of Copenhagen, Copenhagen, Denmark; Center for Microbial Biotechnology, Department of Systems Biology, Technical University of DenmarkWe have managed to develop a S. cerevisiae-based platform with the capacity to deposit eukaryotic membrane proteins to a density of up till 8% of total membrane protein content and identified conditions that allow efficient purification of high quality eukaryotic membrane proteins. We believe that our expression platform is of relevance for any membrane protein as we have managed to express and purify, 7TM receptors, P-type ATPases, K-channels, amino acid/hexose transporters/tranceptors.
|Tue, 04 Nov 11:20 AM - 11:50 AM||Sponsored Presentation (Opportunity Available) |
|Tue, 04 Nov 11:50 AM - 12:50 PM||Problem Solving Roundtable Discussions |
Using Codon Optimisation to Facilitate Expression of Membrane ProteinsMortenNorholmModerator(s): Morton Nu00f8rholm, Ph.D., Academic Entrepreneurial Research Group Leader, DTU Biosustain; Technical University of Denmark, Novo Nordisk Foundation Center for BiosustainabilityCodon optimization choicesHost-related decisionsWhat to expectRecombinant Expression of Toxins and PeptidesJacques DumasModerator: Jacques Dumas, Ph.D., Head, Protein Production Vitry, Biologics SCP, Vitry Research Center, sanofiExpression systemsPeptide size limitationsMammalian vs microbialIs recombinant expression competitive to synthesis?Overcoming Challenges in Protein Expression with BaculovirusModerator: Arnaud Poterzman, Research Director, Integrated Structural Biology, IGBMC/CNRSWhen is baculovirus better?Tools for improving expressionTweaking the system
|Tue, 04 Nov 12:50 PM - 02:00 PM||Luncheon Presentation (Sponsorship Opportunity Available) or Lunch on Your Own |
|Tue, 04 Nov 02:00 PM - 02:30 PM||Dessert Break in the Exhibit Hall with Poster Viewing |
|Tue, 04 Nov 02:30 PM - 02:35 PM||MODULAR APPROACHES, CO-EXPRESSION AND PARTNERS |
Chairpersonu2019s RemarksStefanSchmidtStefan Schmidt, Ph.D., Vice President, Downstream Processing, Rentschler Biotechnology
|Tue, 04 Nov 02:35 PM - 03:05 PM||Modular Approaches to Express Complex Therapeutic Proteins |
Stefan Schmidt, Ph.D., Vice President, Downstream Processing, Rentschler BiotechnologyDifficult to express proteins represent an increasing amount of therapeutic molecules. This causes bioprocessing challenges such as controlling glycosylation, increasing titers and yields, suppressing aggregation and purification without specific affinity resins. Here we demonstrate how to develop modular quasi-platform processes solving these issues. The case studies with examples from various molecule classes highlight successful process design, optimisation strategies and critical manufacturing parameters. Additionally practical advice will be given what to consider when designing a novel molecule.
|Tue, 04 Nov 03:05 PM - 03:35 PM||Enhancing Protein Secretion of Clinically-Important Proteins |
Tsafi Danieli, Ph.D., Head of Protein Expression Facility, Wolfson Centre for Applied Structural Biology, Alexander Silberman Institute of Life SciencesThe ability to improve recombinant protein secretion has significant biological and commercial benefits; Based on high throughput screening experiments, followed by bioinformatics analysis of protein databases of secreted vs. non-secreted proteins, we have developed an algorithm that can predict whether a protein will be poorly or efficiently secreted. We have tested our algorithm on several poorly secreted proteins, and found they all contained specific motifs that we predicted to impair translocation. We then demonstrated that disruption of these motifs by conserved replacement of a few amino acids resulted in a dramatic (up to 15 fold) enhancement of protein secretion in E.coli, insect cells and mammalian cells.
|Tue, 04 Nov 03:35 PM - 04:05 PM||Heterologous Expression and Purification of an Active Human TRPV3 Ion Channel |
Stefan Kol, Ph.D., Protein Biochemist, Novo Nordisk Foundation Centre for Biosustainability, Danish Technical UniversityIn spite of great progress in the TRP-channel characterization, very little is known about their structure and interactions with other proteins at the atomic level. This is mainly caused by difficulties in obtaining functionally active samples of high homogeneity. I will present here the high-level Escherichia coli expression of the human TRPV3 channel, which retains its current inducing activity.
|Tue, 04 Nov 04:05 PM - 04:35 PM||Sponsored Presentation (Opportunity Available) |
|Tue, 04 Nov 04:35 PM - 05:15 PM||Refreshment Break in the Exhibit Hall with Poster Viewing |
|Tue, 04 Nov 05:15 PM - 05:45 PM||Expression of Soluble and Active Interferon Consensus in SUMO Fusion Expression System in E. coli |
Emmanuelle Laurine, Ph.D., PolyTherics Ltd.; The London Bioscience Innovation CentreInterferon consensus (IFN-con) is a non-natural recombinant interferon alpha displaying superior activity compared to most clinically used IFNu03b1-2a. However, production of this therapeutically promising protein remains challenging. Herein, we describe the optimisation of the production of IFN-con in E.coli as a soluble IFN-con. The recoded IFN-con gene was cloned into the Championu2122 pET SUMO expression vector downstream of the SUMO fusion protein under T7lac promoter and expressed in E.coli SHuffleuf7c5 strain. The fusion protein was efficiently expressed in soluble form and IFN-con remained stable following removal of the SUMO fusion partner. In addition, antiviral activity of the produced IFN-con was proven to be greater than activity of IFN u03b1-2a.
|Tue, 04 Nov 05:45 PM - 06:15 PM||Technology for the Consistent Generation of Functional Antibody-Drug Candidates to Membrane Proteins |
. Davis Farmer, Jr., Chairman, MSM Protein TechnologiesMSM Protein Technologies has developed proprietary methods for generating cell lines that over-express complex membrane proteins. We also have displays to present these proteins in their native conformation, highly purified for use in antibody discovery. To date we have generated fully human antibodies to several GPCRs that have met very stringent criteria as drug candidates. We will present an overview of the platforms and examples of antibodies that we have generated.
|Tue, 04 Nov 06:15 PM - 06:45 PM||Expression of USP18 (UBP43) for Enzymatic and Structural Analysis using a Trigger Factor Fusion System in E.Coli and Baculovirus Expression |
Klaus Peter Knobeloch, Ph.D., Head, Liebniz Institute for Molecular PharmacologyProtein modification by ISG15 represents an interferon effector system counteracted by USP18. In mice, we selectively inactivated USP18 protease activity. Enhanced ISGylation increased resistance against influenza-virus infections qualifying USP18 inhibition as a potential antiviral strategy. Using a trigger factor fusion system in E.Coli and baculovirus expression we overcame poor USP18 expression yields, weak enzymatic activity and limited solubility, enabling us to perform inhibitor screens and solve the USP18/ISG15 complex crystal structure.
|Tue, 04 Nov 06:45 PM - 06:45 PM||End of Difficult to Express Proteins |
Visitor Ticket Price
|125 EUR||Choose 1 Short Course|
|195 EUR||Choose 2 Short Courses|
|695 EUR||Premium Package - Advance Registration Rate until 3 October 2014|
|525 EUR||Standard Package - Advance Registration Rate until 3 October 2014|
|375 EUR||Basic Package - Advance Registration Rate until 3 October 2014|
|Academic, Government, Hospital-Affiliate|
|375 EUR||Choose 1 Short Course|
|625 EUR||Choose 2 Short Courses|
|1399 EUR||Premium Package - Early Registration Rate until 5 September 2014|
|1409 EUR||Premium Package - Advance Registration Rate until 3 October 2014|
|1499 EUR||Premium Package - Registration Rate after 3 October 2014 and on-site|
|1049 EUR||Standard Package - Early Registration Rate until 5 September 2014|
|1099 EUR||Standard Package - Advance Registration Rate until 3 October 2014|
|1149 EUR||Standard Package - Registration Rate after 3 October 2014 and on-site|
|749 EUR||Basic Package - Early Registration Rate until 5 September 2014|
|819 EUR||Basic Package - Advance Registration Rate until 3 October 2014|
|869 EUR||Basic Package - Registration Rate after 3 October 2014 and on-site|
|625 EUR||Choose 1 Short Course|
|625 EUR||Choose 2 Short Courses|
|2499 EUR||Premium Package - Early Registration Rate until 5 September 2014|
|2679 EUR||Premium Package - Advance Registration Rate until 3 October 2014|
|2899 EUR||Premium Package - Registration Rate after 3 October 2014 and on-site|
|2129 EUR||Standard Package - Early Registration Rate until 5 September 2014|
|2299 EUR||Standard Package - Advance Registration Rate until 3 October 2014|
|2469 EUR||Standard Package - Registration Rate after 3 October 2014 and on-site|
|1419 EUR||Basic Package - Early Registration Rate until 5 September 2014|
|1599 EUR||Basic Package - Advance Registration Rate until 3 October 2014|
|1779 EUR||Basic Package - Registration Rate after 3 October 2014 and on-site|
Venue Map & Directions
Av. dos Combatentes 45, 1600-042 Lisboa
Featured Hotels in Lisbon
Lisbon Marriott Hotelfrom EUR 103.35
Seven Rivers Luxury Apartmentfrom EUR
Casotasfrom EUR 120
Lisbon Luxury apartment W/ garagefrom EUR 0